Cultured expanded cells are one of the most promoted names in international regenerative medicine, and also one of the most misunderstood. They are often introduced to families as the premium form of stem cell therapy, grown to high numbers in a laboratory and then infused over several visits at overseas clinics. In practice, cultured expansion is a specific laboratory process with a defined research role, a long scientific history, and real limits that shape what it can and cannot do inside the United States.

What Are Cultured Expanded Cells?

Cultured expanded cells are mesenchymal stem cells that have been grown outside the body to increase their numbers. The source tissue can be bone, adipose fat, or umbilical cord. That tissue is broken down, plated in a laboratory dish, and the non adherent material is washed away. The cells that stick to the plate are identified as MSCs, fed with rich growth media, and then detached and reseeded through repeated passaging cycles until the laboratory reaches a target cell count.

Collection and handling are laboratory intensive. A donor tissue is harvested aseptically, the cells are isolated, and each round of growth takes days inside a controlled incubator. Typical seeding densities are around five thousand five hundred cells per square centimeter during expansion, and the cells are counted, washed, and reseeded until the target number is reached. The final product is stored in ten percent DMSO inside negative eighty degree freezers and thawed when a dose is requested.

A typical cultured expansion run is defined less by a fixed collection size than by how many passaging cycles are used to reach the intended cell number. That flexibility is what makes the pathway attractive, and it is also what makes it difficult to regulate and reproduce.

How It All Started

Cultured expanded cells as a modern therapy begin with one Soviet researcher. In the 1960s and 1970s, Dr. Alexander Friedenstein at the Gamaleya Institute in Moscow showed that a small population of plastic adherent cells in bone marrow could form colonies in culture and give rise to bone, cartilage, and fat. Those colony forming unit fibroblasts were the first scientific description of what the field would later call mesenchymal stem cells.

Two decades later, Dr. Arnold Caplan at Case Western Reserve University popularized the term mesenchymal stem cell in a 1991 paper in the Journal of Orthopaedic Research and argued that these cells could be expanded in the laboratory for therapeutic use. A 1999 paper by Mark Pittenger and colleagues in Science then demonstrated that cultured expanded adult human MSCs could differentiate into multiple tissue types. That body of work opened the door to the modern international market in cultured expanded cellular therapy.

What Cultured Expanded Cells Have Done for Patients

Outside the United States, cultured expanded MSCs have become a meaningful part of cellular medicine. Health authorities in Japan, South Korea, Canada, and several European countries have approved cultured MSC products for conditions such as graft versus host disease, Crohn's related fistulas, and certain orthopedic indications. Those approvals are narrow, but they exist, and patients in those countries can access cultured MSCs inside a regulated system.

Inside the United States, the pathway has been far more restricted. The FDA classifies cultured expansion as more than minimal manipulation, which moves the final product into drug regulation and requires a full Investigational New Drug application and a Biologics License Application before it can be marketed. For most of the last two decades the answer for patients in the U.S. has been that cultured expanded MSCs are not approved for use. A narrow exception is Ryoncil, the first FDA approved MSC therapy in the United States, cleared at the end of 2024 for pediatric steroid refractory acute graft versus host disease. What began in a Moscow laboratory has become a global research and therapy category, but inside the U.S. the approved list is still very short. For patients who do not fit that narrow list, cultured expanded MSCs are not available through an approved domestic pathway.

Autism is a separate story. Cultured expanded MSCs have never been approved for autism, and there is no U.S. approved clinical pathway for this use. The most visible offering in this space has been international clinics, which is why many American families have traveled to Panama, Mexico, Ukraine, and other destinations in search of expanded MSC infusions for their children. Those trips have been a central part of the autism cell therapy conversation for years, and they are also the exact scenario Neuro Free was founded to respond to. The FDA has issued public warnings about overseas stem cell treatments and pursued action against domestic clinics importing or administering cultured expanded products outside the approved pathways.

The practical challenges stack on top of that. Cultured expansion depends on repeated passaging, which is the process of detaching cells from a dish and replating them to allow continued growth. Each cycle changes the cells. Live cell viability is highest through the earliest growth cycles and declines with additional passaging. Surface markers drift over time, so a product harvested at passage two is not biologically identical to the same line at passage six or eight. Contamination remains a real concern because every open step in the laboratory introduces risk, and current testing can only screen for known cancer cell lines rather than confirm safety against unknown ones. For families looking specifically at autism care, cultured expanded MSCs are not approved in the U.S., carry the logistical and regulatory risk of overseas care, and deliver a product whose biological identity changes with every passage.

Limits a Patient Should Weigh

Cultured expanded MSCs are largely not approved for use in the United States. With the narrow exception of Ryoncil for pediatric steroid refractory acute graft versus host disease, cultured expansion falls under drug regulation and requires a full FDA approval pathway before a product can be used in domestic clinical care. Any U.S. clinic offering cultured expanded cells outside that framework is operating outside the approved system.

Repeated passaging changes the cells. Expansion relies on detaching and reseeding cells through multiple growth cycles. Surface markers drift with passaging, so the biological identity of the product at harvest is not the same as its identity several cycles later. A patient and physician planning around a specific cellular profile are working from a moving target.

Viability falls over time. Cultured MSCs are most effective through the earliest growth cycles. With additional passaging, live cell numbers and activity both decline. The product that looks strongest on paper is not always the product that reaches the patient.

Contamination is a structural risk. Every open step in a laboratory, from the tissue harvest to each passage, introduces exposure. Current screening can detect known cancer cell lines and common contaminants, but it cannot confirm the absence of unknown ones. The FDA points to this risk as a core reason cultured expansion is treated as drug manufacture rather than tissue handling.

Storage depends on DMSO and deep freeze handling. Cultured expanded cells are held in ten percent DMSO inside negative eighty degree bio freezers and thawed for use. That is a workable system, but it introduces a chemical carrier into the final infusion and requires tight handling at every link in the chain.

Overseas treatment carries its own costs. Families who pursue cultured expanded MSCs outside the U.S. take on international travel, limited medical oversight, and out of pocket expense for a therapy that cannot be followed up or continued inside a domestic physician led setting.

Approved uses are narrow. Even where cultured expanded MSCs are approved internationally, the approvals cover specific conditions such as graft versus host disease, Crohn's related fistulas, and certain orthopedic indications. Cultured expanded cells have not been approved for most of the chronic conditions families hear about in connection with stem cells, such as ongoing care for neurological conditions or degenerative diseases. A patient looking for cellular therapy outside those narrow lists will generally not find cultured expanded MSCs as an approved option.

A New Frontier: Neuro Free

For families looking at cellular therapy as part of autism care, one of the newer developments in the United States is Neuro Free. It is the only U.S. based patented cellular therapy developed specifically for autism spectrum disorder, aimed at improving brain function and reducing neurological inflammation in pediatric and young patients with autism. Treatment is available for ages 2 to 22, with most patients treated between 2 and 20.

Neuro Free was founded in 2016 by physicians who had watched families travel overseas in search of stem cell options they could not find at home. Those trips were often expensive, emotionally difficult, and carried out with limited medical oversight. The program was built to offer that pathway inside a physician led setting in the United States and Canada.

A treatment cycle begins with tissue donated by the mother and collected by a plastic surgeon. The harvest is then developed through a patented process carried out inside an FDA registered laboratory, with the patent and the laboratory held by separate entities. On treatment day, the cells are delivered to the child through an IV infusion that runs for about two and a half hours. Many children report feeling sleepy during the infusion, there are no known side effects, and noticeable changes are typically reported within a few hours of treatment.

Several points set the Neuro Free program apart from cultured expanded cellular therapy:

• No repeated passaging. Neuro Free is built around the perivascular fraction where MSCs naturally reside, rather than growing cells through multiple expansion cycles. The product is not subject to the marker drift and viability decline that come with serial passaging.
• Domestic, physician led care. Treatment is delivered inside a U.S. and Canadian physician led setting, rather than the overseas clinics that have historically dominated the cultured expanded autism market.
• Documented cell counts. Each unit is released with recorded total nucleated cells, total cells, and live cell viability, typically reported between 95 and 100 percent. Cultured expansion does involve counting, but the patient facing reporting model is not the same.
• Repeatable treatment. The full harvest is processed and stored at negative 80 degrees Celsius, and doses are released on request. A child's care plan can include multiple scheduled infusions without depending on overseas travel or additional expansion runs.
• Designed for injection and infusion. The program is built for both IV infusions and injections within a regulated domestic framework, rather than depending on international treatment destinations.

Sources

• Friedenstein, A. J., Chailakhjan, R. K., Lalykina, K. S. "The Development of Fibroblast Colonies in Monolayer Cultures of Guinea Pig Bone Marrow and Spleen Cells." Cell and Tissue Kinetics, 1970.
• Caplan, A. I. "Mesenchymal Stem Cells." Journal of Orthopaedic Research, 1991.
• Pittenger, M. F., et al. "Multilineage Potential of Adult Human Mesenchymal Stem Cells." Science, 1999.
• U.S. Food and Drug Administration. "FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid Refractory Acute Graft Versus Host Disease" (Ryoncil).
• U.S. Food and Drug Administration. "Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue Based Products: Minimal Manipulation and Homologous Use." Guidance for Industry.
• U.S. Food and Drug Administration. "Important Patient and Consumer Information About Regenerative Medicine Therapies."